Skip to main content

Table 6 Socio-demographic and substance use profile and use of other medication by patients in treatment for substance use disorders in Belgium, who have been prescribed gabapentin between 2008 and 2014, and a sub-sample of patients who might have used gabapentin at a dose that could indicate abuse

From: Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011–2014): a cross-sectional study

 

Prescribed gabapentin (N = 649)

Abuse gabapentin (N = 56)

 

N

%

N

%

Regiona

 Flanders

403

62.1%

36

64.3%

 Wallonia

200

30.8%

16

28.6%

 Brussels

46

7.1%

4

7.1%

Program type

 Medical Social Care Center

31

4.8%

3

5.4%

 Specialized outpatient service

69

10.6%

4

7.1%

 Crisis center

12

1.9%

0

0.0%

 Therapeutic community

31

4.8%

2

3.6%

 Mental health service

28

4.3%

2

3.6%

 Psychiatric hospital

266

41.0%

24

42.9%

 General hospital

212

32.7%

21

37.5%

Past treatment

 No

162

25.0%

12

21.4%

 Yes

455

70.1%

42

75.0%

 Unknown/missing

32

4.9%

2

3.6%

Source of referral

 Own initiative

293

45.2%

30

53.6%

 Family or friends

97

15.0%

5

8.9%

 Outpatient center for substance use disorders

10

1.5%

0

0.0%

 General practitioner

99

15.3%

6

10.7%

 Hospital or other medical service

93

14.3%

12

21.4%

 Social service

5

0.8%

1

1.8%

 Police or justice

36

5.6%

0

0.0%

 Other

8

1.2%

2

3.6%

 Unknown/missing

8

1.2%

0

0.0%

Education

 No

7

1.1%

0

0.0%

 Primary education

108

16.6%

8

14.3%

 Secondary education

383

59.0%

31

55.4%

 Higher education

100

15.4%

11

19.6%

 Unknown/missing

51

7.9%

6

10.7%

Main substance

 Opiates

5

0.8%

1

1.8%

 Heroin

36

5.6%

0

0.0%

 Methadone

9

1.4%

1

1.8%

 Buprenorphine

1

0.2%

0

0.0%

 Other opiates

8

1.2%

1

1.8%

  Opioids (total)

(59)

(9.1%)

(3)

(5.4%)

 Cocaine

27

4.2%

1

1.8%

 Cocaine (other)

5

0.8%

0

0.0%

  Cocaine (total)

(32)

(4.9%)

(1)

(1.8%)

 Amphetamines

15

2.3%

0

0.0%

 Stimulants (other)

2

0.3%

0

0.0%

  Stimulants (total)

(17)

(2.6%)

(0)

(0.0%)

 Hypnotics and sedatives

5

0.8%

0

0.0%

 Barbiturates

2

0.3%

0

0.0%

 Benzodiazepines

44

6.8%

4

7.1%

 Other hypnotics and sedatives

8

1.2%

0

0.0%

  Hypnotics and sedatives (total)

(59)

(9.1%)

(4)

(7.1%)

 Cannabis

42

6.5%

2

3.6%

 Alcohol

423

65.2%

45

80.4%

 Other

17

2.6%

1

1.8%

Frequency of use main substance

 Not used in the last month

41

6.3%

1

1.8%

 Once per week or less

30

4.6%

3

5.4%

 Two to six times per week

90

13.9%

8

14.3%

 Daily

451

69.5%

41

73.2%

 Unknown/missing

37

5.7%

3

5.4%

Age first use main substance

 Median age

18

 

17.5

 

Ever injecting behavior

 Ever injected but not currently

41

6.3%

2

3.6%

 Currently injecting

18

2.8%

2

3.6%

 Never injected

481

74.1%

40

71.4%

 Unknown/missing

109

16.8%

12

21.4%

Year of start treatment

 2011

109

16.8%

9

16.1%

 2012

174

26.8%

16

28.6%

 2013

167

25.7%

12

21.4%

 2014

199

30.7%

19

33.9%

Nationality

 Belgian

614

94.6%

53

94.6%

 EU citizen but not Belgian

11

1.7%

3

5.4%

 Non-EU citizen

10

1.5%

0

0.0%

 Unknown/missing

14

2.2%

0

0.0%

Professional situation

 Regular job

83

12.8%

4

7.1%

 Student

4

0.6%

1

1.8%

 Economically non-active

426

65.6%

41

73.2%

 Unemployed

85

13.1%

6

10.7%

 Other

29

4.5%

4

7.1%

 Unknown/missing

22

3.4%

0

0.0%

  1. aOf all treatment programs participating in the TDI registration, 54% is located in Flanders, 32% in Wallonia and 14% in Brussels